Abstract
BackgroundCD3 bispecific antibodies (CD3-bsAbs) require binding of both a tumor-associated surface antigen and CD3 for their immunotherapeutic effect. Their efficacy is, therefore, influenced by the tumor uptake and the extracellular...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have